Chemotherapy for progressive low-grade gliomas in children older than ten years: The Dana-Farber experience
Chemotherapy for progressive low-grade gliomas in children older than ten years: The Dana-Farber experience
复制标题
DOI：
10.1080/08880010390232709
复制
发表时间：
2003-10-01
影响因子：
1.7
通讯作者：
Kieran, MW
中科院分区：
文献类型：
--
作者：
Heath, JA;Turner, CD;Kieran, MW
这项回顾性研究的目的是检查10岁以上儿童低级别胶质瘤的临床和放射学反应率和化疗毒性。在1999年6月至2001年1月期间，连续7名年龄在10至18岁之间的儿童接受了长春新碱和卡铂硫鸟嘌呤、丙卡嗪、CCNU[洛莫司汀]和长春新碱（TPCV）治疗进展性低级别胶质瘤。所有7名儿童完成了为期10周的长春新碱和卡铂诱导疗程；3例患者在卡铂过敏反应后，在治疗维持阶段改用TPCV。总体而言，4例患者对化疗有放射学反应（3例部分反应，1例轻微反应，客观反应率为57%），2例患者病情稳定。1例患者在治疗期间出现进展，1例患者在停止治疗后出现进展，31个月后。在此报告时，结果无进展生存率为71%。中位随访时间为32个月（范围25-42个月）。血液学毒性是常见的，但没有导致停止治疗。未观察到其他显著的治疗相关毒性。结果表明，10岁以上儿童的临床反应/疾病稳定率与年龄较小的儿童没有明显差异。因此，对10岁以上儿童进行性低级别胶质瘤进行化疗的前瞻性临床试验是必要的。
The Purpose of this retrospective study was to examine the clinical and radiographic response rates to and toxicity of chemotherapy for low-grade gliomas in children older than 10 years of age. Between June 1999 and January 2001, seven consecutive children between the ages of 10 and 18 were treated with vincristine and carboplatin thioguanine, procarbazine, CCNU[lomustine], and vincristine (TPCV) for progressive low-grade gliomas. All 7 children completed a 10-week induction course of vincristine and carboplatin; 3 were switched to TPCV during the maintenance phase of therapy after developing an allergic reaction to carboplatin. Overall, 4 patients had a radiographic response to treatment with chemotherapy (3 partial responses and I minor response: objective response rate of 57%), and 2 more showed stable disease. One patient progressed while on treatment and I patient progressed off treatment, and after 31 months had elapsed. 7 he resulting progression-free survival at the time of this report was 71%. The median duration of follow-up was 32 months (range 25-42 months). Hematologic toxicity was common, but did not result in cessation of therapy. No other significant treatment-related toxicities were observed. The results suggest that the clinical response/disease stabilization rate in children older than 10 years of age does not differ markedly from that observed in younger children. A prospective clinical trial of chemotherapy for progressive low-grade gliomas in children older than 10 years is therefore warranted.